159 related articles for article (PubMed ID: 38346748)
1. Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Nonomiya Y; Nakayama I; Kobayashi K; Amakawa Y; Shibata N; Soejima A; Kawakami K; Shimizu H; Takahari D; Kawai S; Hara F; Takano T; Yamaguchi K; Yamaguchi M
Biol Pharm Bull; 2024; 47(2):411-416. PubMed ID: 38346748
[TBL] [Abstract][Full Text] [Related]
2. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
[TBL] [Abstract][Full Text] [Related]
4. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Modi S
Future Oncol; 2021 Sep; 17(26):3415-3423. PubMed ID: 34263665
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
10. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
11. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
[TBL] [Abstract][Full Text] [Related]
13. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
[TBL] [Abstract][Full Text] [Related]
14. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
[TBL] [Abstract][Full Text] [Related]
16. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Shitara K
Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis.
Dowling GP; Daly GR; Keelan S; Boland F; Toomey S; Hill ADK; Hennessy BT
Clin Breast Cancer; 2023 Dec; 23(8):847-855.e2. PubMed ID: 37775347
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]